ARIBIO Group Unveils Integrated Vision Linking "Prevention, Treatment and Management"

[Financial News] "Everyone should be able to live as themselves until the very end. This is Aribio's vision."
At the "2026 Vision Proclamation Ceremony: Toward the Future," held on the 1st at Seoul Dragon City in Yongsan-gu, Seoul, Jeong Jae-jun, chairman of ARIBIO Group, made the declaration and unveiled a strategy for the three companies to establish business structures focused respectively on dementia prevention, treatment and management.
Aribio Lab will develop preventive technologies, including Alzheimer's vaccines, while Aribio will oversee the development and commercialization of dementia treatments. ARIBIO Holdings plans to connect the three companies' businesses by expanding investments in data infrastructure and healthcare, building on its lighting and electrical operations.
Aribio is a biotech company focused on developing treatments for Alzheimer's disease, with the release of global Phase 3 results for its key candidate, "AR1001," scheduled for November. Around 150 people, including Chairman Jeong, key employees from the three companies and external guests, attended the event.
Aribio Lab is pursuing the development of Alzheimer's vaccines based on an adjuvant platform. It is currently conducting a Phase 2 clinical trial of a shingles vaccine, a Phase 1 trial of a hepatitis B vaccine and a Phase 2 trial of a therapeutic vaccine. The company plans to apply the adjuvant technology and clinical experience acquired during the shingles vaccine development process to its Alzheimer's vaccine. It aims to secure key Phase 2 results for the shingles vaccine in 2026-2027 and begin preclinical studies of the Alzheimer's vaccine. For 2028-2029, it plans to enter Phase 3 trials for the shingles vaccine and prepare for commercialization.
In the treatment division, Aribio is scheduled to release Phase 3 results for AR1001, which it is developing. The global Phase 3 trial was conducted at approximately 230 institutions in 13 countries, with 1,535 participants enrolled. Of these, 1,348 completed the 52-week main trial. The company will present key results at "CTAD 2026," to be held in Boston on November 16. Based on the trial results, it plans to prepare a New Drug Application (NDA) for the U.S. Food and Drug Administration (FDA) in 2026 and proceed with the application and approval process in 2027-2028.
Commercialization agreements for AR1001 have been signed in five regions. Aribio is also pursuing an expansion of its indications to include stroke, Parkinson's disease, vascular dementia and traumatic brain injury. Its follow-up candidate, the Lewy body dementia treatment "AR1005," is in Phase 2 trials, with the company aiming to secure key results in 2027. "AR1004," a treatment for mild cognitive impairment, has received approval for its Phase 2 investigational new drug (IND) application.
ARIBIO Holdings oversees the group's investments and business management. Building on its existing lighting and electrical operations, it is expanding into construction projects for semiconductor plants and artificial intelligence (AI) data centers. It also plans to enter the fields of AI data infrastructure, electroceuticals and healthcare.
Jeong emphasized, "Today, as we clearly set out the group's identity, structure and growth roadmap, marks the starting point at which the three pillars of treatment, prevention and management converge into a single vision." He added, "As the group already possesses extensive clinical data, regulatory response capabilities, global partnerships and an execution foundation, we will use ARIBIO Holdings as our hub to take on not only neurodegenerative brain diseases such as dementia and Parkinson's disease, but also the broader challenges of aging."

[email protected] Jeong Sang-hee Reporter